Published on : May 20, 2016
ALBANY, New York, May 20, 2016: The company offers a top-class collection of reports for the pharmaceutical industry, the latest of which is titled “Anticoagulants-Market Insights & Drugs Sales Forecast (VTE & AF)-2020.” This report includes major and minor elements of the global anticoagulants market that are together responsible for shaping the future of this market. Each factor is taken into consideration while calculating the market size for the forecast period of 2015 to 2020. The report thus delivers vital insight on the global anticoagulants market in terms of drug sales and market forecast for venous thromboembolism and atrial fibrillation.
The introductory passage of the report on the global anticoagulants market is a representation of the key factors that will influence the market share of anticoagulants in the pharmaceutical industry from 2015 to 2020.
The introductory piece on the global anticoagulants market provides brief notes on three major anticoagulants: Warfarin, NOAC, and low molecular weight heparins. Warfarin is one of the most commonly found anticoagulants against thrombosis and thromboembolism. Low molecular weight heparins is a class of anticoagulants used in the treatment of deep vein thrombosis. New oral anticoagulants are used in the treatment of AF.
Click here to get more info with TOC in a PDF Format: https://www.researchmoz.us/enquiry.php?type=S&repid=714514
The report moves further into the details of the global anticoagulants market and the roles they play in the treatment of VTE and AF. Each medical complication is tagged separately and explained according to the disease epidemiology, the current competitive landscape in terms of treating AF and VTE, the treatment algorithm, and the details and goals of each major treatment available in the global anticoagulants market. The current key anticoagulants that are receiving enhanced focus in terms of marketing are NOACs and reversal agents.
The report also explains the structure of the global anticoagulants market in terms of geography. It reveals the major statistics of the anticoagulants markets in the U.S., Europe, and Japan, apart from the assessment of the global anticoagulants market. Each region is described in terms of overall market share and the market share of anticoagulants used in the treatment of AF and VTE separately.
The report creates detailed representations of the global anticoagulants market in terms of each major marketed drug. The drug profile of each anticoagulant includes its advantages and complications, safety levels, efficacy, cost, side effects, drug sales globally and regionally, drug sales according to indication, SWOT analysis, and a clinical trial information.
The drugs explained in the report include Xarelto (rivaroxaban), Pradaxa (dabigatran etexilate mesylate), Eliquis(Apixaban), Savaysa (edoxaban
To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on [email protected]